NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.50 Consensus PT from Analysts

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $14.50.

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. increased their price target on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company dropped their price objective on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th.

Insider Transactions at NeuroPace

In related news, major shareholder Ltd. Kck sold 223,991 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the completion of the sale, the insider now owns 5,270,845 shares of the company’s stock, valued at $28,726,105.25. This represents a 4.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders have sold 257,590 shares of company stock valued at $1,437,916. 22.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NeuroPace

Several hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its holdings in shares of NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after acquiring an additional 16,007 shares during the period. Geode Capital Management LLC raised its position in NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares in the last quarter. State Street Corp lifted its stake in NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Financial Advocates Investment Management lifted its stake in NeuroPace by 20.0% during the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after purchasing an additional 80,324 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

NeuroPace Price Performance

Shares of NPCE opened at $11.53 on Friday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The company’s fifty day simple moving average is $8.81 and its 200 day simple moving average is $7.72. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15. The company has a market cap of $344.15 million, a price-to-earnings ratio of -11.53 and a beta of 2.05.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. During the same period in the previous year, the business earned ($0.28) EPS. On average, research analysts forecast that NeuroPace will post -1 earnings per share for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.